Masimo (NASDAQ:MASI) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday.

A number of other equities analysts have also commented on MASI. BTIG Research raised shares of Masimo from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a research report on Monday, August 14th. Zacks Investment Research lowered shares of Masimo from a “buy” rating to a “hold” rating in a research report on Tuesday, October 3rd. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $108.00 price target on shares of Masimo in a research report on Friday, November 3rd. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. Masimo currently has a consensus rating of “Hold” and a consensus price target of $97.17.

Shares of Masimo (NASDAQ MASI) traded up $0.48 on Thursday, hitting $86.00. 396,352 shares of the stock traded hands, compared to its average volume of 340,552. The company has a market capitalization of $4,418.92, a price-to-earnings ratio of 32.77, a PEG ratio of 2.88 and a beta of 0.72. Masimo has a 52 week low of $63.71 and a 52 week high of $104.71.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, October 31st. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.53 by $0.17. The company had revenue of $193.69 million for the quarter, compared to analyst estimates of $189.01 million. Masimo had a net margin of 45.83% and a return on equity of 22.17%. The company’s revenue was up 15.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.52 earnings per share. analysts anticipate that Masimo will post 2.95 earnings per share for the current fiscal year.

In other Masimo news, Director Steven Barker sold 10,000 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $90.00, for a total transaction of $900,000.00. Following the sale, the director now directly owns 73,249 shares in the company, valued at $6,592,410. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Yongsam Lee sold 18,198 shares of the stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $88.85, for a total transaction of $1,616,892.30. Following the sale, the executive vice president now owns 70,800 shares in the company, valued at $6,290,580. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 53,074 shares of company stock worth $4,737,245. 16.60% of the stock is owned by insiders.

Institutional investors have recently made changes to their positions in the business. Fortaleza Asset Management Inc. acquired a new stake in Masimo during the second quarter worth about $106,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Masimo by 13.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,018 shares of the medical equipment provider’s stock worth $184,000 after buying an additional 236 shares in the last quarter. DekaBank Deutsche Girozentrale grew its stake in Masimo by 78.3% during the third quarter. DekaBank Deutsche Girozentrale now owns 2,106 shares of the medical equipment provider’s stock worth $182,000 after buying an additional 925 shares in the last quarter. Advisor Group Inc. grew its stake in Masimo by 38.4% during the second quarter. Advisor Group Inc. now owns 2,361 shares of the medical equipment provider’s stock worth $216,000 after buying an additional 655 shares in the last quarter. Finally, Daiwa Securities Group Inc. acquired a new stake in Masimo during the second quarter worth about $219,000. Hedge funds and other institutional investors own 83.74% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/12/09/masimo-masi-downgraded-to-sell-at-bidaskclub.html.

Masimo Company Profile

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.

Analyst Recommendations for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Co. and related companies with MarketBeat.com's FREE daily email newsletter.